Amneal Pharmaceuticals (AMRX) to Release Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) will release its earnings data before the market opens on Friday, November 8th. Analysts expect Amneal Pharmaceuticals to post earnings of $0.11 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.570-0.630 EPS.Investors that wish to register for the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $701.78 million during the quarter, compared to the consensus estimate of $657.43 million. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Stock Down 1.2 %

AMRX opened at $8.47 on Friday. The business’s fifty day simple moving average is $8.53 and its 200 day simple moving average is $7.41. Amneal Pharmaceuticals has a 52 week low of $3.72 and a 52 week high of $8.95. The stock has a market cap of $2.61 billion, a PE ratio of -15.13 and a beta of 1.18.

Analysts Set New Price Targets

AMRX has been the topic of a number of research reports. Barclays raised their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Finally, Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.